GENE ONLINE|News &
Opinion
Blog

2021-01-24| ChinaCOVID-19

Expecting Lunar New Year Travel Rush, China Races to Build Giant Quarantine Center

by Tyler Chen
Share To

Outside Shijiazhuang, Hebei province, over 4,000 construction workers are building a giant quarantine center of 4,156 units that can house COVID-19 patients within days of diagnosis.

 

New Wave of COVID-19 Cases

According to WHO’s data, China has 99,414 confirmed cases of COVID-19 with 4,808 deaths as of January 21st. As the Lunar New Year approaches, China expects a new wave of COVID-19 cases where city residents are traveling across the country to meet their families. To alleviate the burden on the healthcare system, China has started constructing a new quarantine location on January 13th on the outskirts of Northern China.

 

Quarantine Unit

Each unit in the quarantine center is equipped with basic facilities, including internet, bathroom, bedroom, air conditioning, etc. District 1 is currently moving to the last phase. Most of the infrastructures are done with air conditioning and water heaters waiting to be installed. Within days, China has successfully delivered 606 units and is estimated to reach 1,779 in total by the end of January.

 

Individual Testing of COVID-19

Furthermore, China has scheduled to perform a COVID-19 testing plan in the quarantine center for each individual. Every personnel and quarantine related parties will undergo a nucleic acid amplification testing (NAAT) for COVID-19 from January 20 to 22nd, and there will be 28 testing companies for professional and efficient screening.

Related Article: COVID-19: South Korea and Japan Make New Plans to Fight the Pandemic

References
  1. http://www.gov.cn/xinwen/2021-01/19/content_5581124.htm#1
  2. http://www.sjz.gov.cn/col/1609405465981/2021/01/21/1611190892875.html
  3. http://www.sjz.gov.cn/col/1596014213243/2021/01/20/1611105496040.html
  4. https://www.163.com/dy/article/G0SLI3JB0514R9KE.html

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Investigate the Current Status of Rivaroxaban Generic Drug Application in China
2023-03-01
The U.S. COVID-19 Public Health Emergency Ends in May, but FDA’s EUA Authority Remains
2023-02-01
Novavax Begins Phase 2 For COVID-19/Influenza Combination And Stand-Alone Flu Shots
2023-01-03
LATEST
35% Of Better Therapeutics’ Staff to be Cut to Extend the Company’s Runway
2023-03-27
Pharming’s Joenja Racks Up FDA Approval For Rare Primary Immunodeficiency
2023-03-27
Ways to Reduce Carbon Emission in Cement Manufacturing
2023-03-26
Moderna Injects $76 Million To Kickstart Lipid Nanoparticle Delivery Partnership With Generation Bio
2023-03-24
Shining a Light on Oncology with Rakuten Medical Co-CEO Takashi Toraishi
2023-03-23
Incyte’s Zynyz Secures FDA Approval for Treating a Rare and Aggressive Skin Cancer
2023-03-23
Biohaven Licenses TYK2/JAK1 Dual Inhibitor From China’s Highlight In $970 Million Pact
2023-03-23
Scroll to Top